Quercetin for Coronary Artery Disease

(Q-CABG Trial)

Not currently recruiting at 1 trial location

Overseen By Michel Carrier, MD

Age: 18+

Sex: Any

Trial Phase: Phase 2

Sponsor: Montreal Heart Institute

Must not be taking: Quinolone, Quercetin

Disqualifiers: Renal insufficiency, Liver disease, Cirrhosis, others

Prior Safety Data This treatment has passed at least one previous human trial

Approved in 1 Jurisdiction This treatment is already approved in other countries

Compensation: Varies

Number of Visits: 2

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial explores how quercetin, a plant-based compound, might reduce inflammation and slow cell aging during heart bypass surgery. It compares the effects of quercetin against a placebo to determine its impact on patients with coronary artery disease. Individuals who have recently had a heart attack or experience stable chest pain and are scheduled for heart surgery might be suitable candidates. As a Phase 2 trial, the research focuses on measuring the treatment's effectiveness in an initial, smaller group of participants.

Will I have to stop taking my current medications?

The trial does not specify if you need to stop taking your current medications, but you cannot participate if you are taking quinolone antibiotics or quercetin supplements.

Is there any evidence suggesting that quercetin is likely to be safe for humans?

Research has shown that quercetin, a natural substance in fruits and vegetables, is generally safe. It possesses properties that help reduce harmful substances and swelling in the body. Studies suggest quercetin may benefit heart health, prompting its testing for coronary artery disease.

Users of quercetin have not reported major safety issues, indicating it is usually safe. However, some might experience mild side effects like headaches or an upset stomach. As this study is in the early stages, researchers continue to carefully assess its safety and effectiveness.

Overall, quercetin appears to be a safe choice for most people, and researchers remain optimistic about its potential benefits for heart health. ^{1 2 3 4 5}

Why do researchers think this study treatment might be promising for coronary artery disease?

Unlike the standard treatments for coronary artery disease, which often include medications like statins and beta-blockers, quercetin offers a unique approach as it is a naturally occurring flavonoid found in many fruits and vegetables. Researchers are excited about quercetin because it may have antioxidant and anti-inflammatory properties that target blood vessel health, potentially reducing plaque buildup and improving heart function. This novel mechanism of action sets quercetin apart from traditional therapies, offering a promising alternative for patients with coronary artery disease.

What evidence suggests that quercetin might be an effective treatment for coronary artery disease?

Research has shown that quercetin, which participants in this trial may receive, has strong effects that protect the heart and blood vessels. It can reduce inflammation and support heart health. These benefits might be useful during coronary artery bypass surgery by lowering inflammation and possibly aiding recovery. ^{1 3 6 7 8}

Who Is on the Research Team?

Michel Carrier, MD

Principal Investigator

Montreal Heart Institute

Are You a Good Fit for This Trial?

This trial is for adults who've had a heart attack in the last 30 days or have stable angina, awaiting coronary artery bypass surgery. They must speak French or English and consent to participate. Excluded are those without recent heart attacks, with infections, severe kidney/liver disease, estrogen-dependent tumor history, flavonoid intolerance, or taking certain medications.

Inclusion Criteria

I had a heart attack in the last 30 days or my chest pain is stable.

To be able to give free and enlighten consent

I am hospitalized and waiting for heart bypass surgery.

Exclusion Criteria

I have had breast cancer or another estrogen-dependent tumor before.

You are unable to tolerate flavonoids, niacin, or ascorbic acid.

I am currently taking a quinolone medication.

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

1-2 weeks

Pre-surgery Treatment

Participants receive quercetin or placebo starting 2 days before surgery

2 days

1 visit (in-person)

Surgery and Immediate Post-surgery

Participants undergo coronary artery by-pass graft surgery and receive treatment during hospitalization

Up to 10 days

In-patient stay

Follow-up

Participants are monitored for health status and changes post-surgery

8 to 12 weeks

1 visit (in-person)

What Are the Treatments Tested in This Trial?

Interventions

• Quercetin

Trial Overview

The study examines Quercetin's potential to reduce inflammation and slow cell aging during coronary bypass surgery compared to a placebo. Participants will be randomly assigned to receive either Quercetin or an inactive substance.

How Is the Trial Designed?

Group I: Quercetin Active Control 1 Intervention

Patients receiving 500 mg quercetin twice daily

Group II: Placebo Placebo Group 1 Intervention

Patients receiving placebo twice daily

Quercetin is already approved in United States for the following indications:

Approved in United States as Quercetin for:

• Herbal Supplementation
• Nonbacterial Chronic Prostatitis
• Interstitial Cystitis

Who Is Running the Clinical Trial?

Montreal Heart Institute

Lead Sponsor

Trials

125

Recruited

85,400+

Citations

1.

pmc.ncbi.nlm.nih.gov

pmc.ncbi.nlm.nih.gov/articles/PMC9412669/

Potential Pharmaceutical Applications of Quercetin in ...

Quercetin (3,3′,4′,5,7-pentahydroxyflavone) belongs to flavonols ... quercetin, was correlated with higher risks of coronary artery disease [156].

2.

sciencedirect.com

sciencedirect.com/science/article/pii/S2590257125000057

Anti-inflammatory potential of quercetin: From chemistry ...

Similarly, quercetin exhibits cardioprotective effect in experimental models of cardiac injury through antioxidant and anti-inflammatory properties (Ferenczyova ...

3.

pmc.ncbi.nlm.nih.gov

pmc.ncbi.nlm.nih.gov/articles/PMC10674654/

Quercetin as a Therapeutic Product: Evaluation of Its ...

Quercetin has antioxidant, anti-inflammatory, cardioprotective, antiviral, and antibacterial effects. It is found to be beneficial against cardiovascular ...

4.

researchgate.net

researchgate.net/publication/283029062_The_Efficacy_of_Quercetin_in_Cardiovascular_Health

The Efficacy of Quercetin in Cardiovascular Health

The aims of this review are to summarise the current knowledge on the bioavailability and metabolism of quercetin as well as discuss the current ...

5.

mdpi.com

mdpi.com/2072-6643/17/9/1579

The Effects of Quercetin on Vascular Endothelium ...

This flavonoid has received particular attention for its powerful antioxidant, anti-inflammatory, and vascular-protective properties [4,5]. Quercetin (3,3′,4′,5 ...

6.

sciencedirect.com

sciencedirect.com/science/article/pii/S187853522300343X

A critical review on quercetin bioflavonoid and its derivatives

Hypertension, dyslipidemia, diabetes, and obesity are also causes of cardiovascular disease. So, quercetin has been proposed for cardiovascular disease ...

7.

mdpi.com

mdpi.com/2218-273X/15/1/151

The Role of Quercetin, a Flavonoid in the Management ...

Quercetin (Qu), a flavonoid found in vegetables and fruits, has been shown to significantly prevent and treat pathogenesis by reducing oxidative stress, ...

8.

frontiersin.org

frontiersin.org/journals/immunology/articles/10.3389/fimmu.2021.689044/full

Potential Implications of Quercetin in Autoimmune Diseases

Quercetin has reportedly attenuated rheumatoid arthritis, inflammatory bowel disease, multiple sclerosis, and systemic lupus erythematosus in humans or animal ...